Clinical Trial Detail

NCT ID NCT02747537
Title Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

Advanced Solid Tumor

Therapies

Irinotecan + Sorafenib

Age Groups: child adult

Additional content available in CKB BOOST